RxDoctor Payments Data

Simon Fishman, MD

Neurology · Alexandria, VANPI 1578654968

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $135,930 of the $206,568 with a category attached, or 65.8%. Biogen accounts for 61.0% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $50,306 and has fallen 58.7% since, to $20,766 in 2025. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$206,568in general payments, 2019–2025

Across 1,602 payments — averaging $128.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$126K
  • AbbVie$46K
  • Teva Pharmaceuticals USA, Inc.$11K
  • Novartis$3K
  • EMD Serono, Inc.$3K
  • Amgen$2K
  • plus $16K from 54 others
$1,421,023in research payments, 2019–2025

Across 261 payments — averaging $5444.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$832K
  • Novartis$180K
  • Eli Lilly$159K
  • Novo Nordisk AS$131K
  • Genentech, Inc.$86K
  • EMD Serono, Inc.$28K
  • plus $5K from 1 others

What the payments were for

  • Consulting fees$20,68210%
  • Speaking & faculty fees$135,93066%
  • Travel & lodging$12,1276%
  • Food & beverage$37,74918%
  • Education$810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen262$126,041
AbbVie(2 entities)327$45,761
Teva Pharmaceuticals USA, Inc.54$10,843
Novartis157$3,425
EMD Serono, Inc.89$2,994
Amgen(2 entities)71$1,726
Lilly USA, LLC67$1,504
Lundbeck LLC44$1,109
Medtronic11$957
Bristol Myers Squibb56$895
Genentech USA, Inc.70$832
TG Therapeutics, Inc.8$670
Pfizer25$608
UCB, Inc.30$572
Axsome Therapeutics, Inc.11$556
AstraZeneca(2 entities)18$551
MDD US Operations, LLC11$533
Neurelis, Inc.28$515
Argenx US, Inc.21$449
Eisai Inc.29$438
Biohaven Pharmaceutical Holding Company Ltd.9$399
Biohaven Pharmaceuticals, Inc.13$392
Harmony Biosciences LLC16$385
Merz Pharmaceuticals, LLC7$296
E.r. Squibb & Sons, L.L.C.8$269
Neurocrine Biosciences, Inc.8$268
Genentech, Inc.3$235
Acorda Therapeutics, Inc12$220
Averitas Pharma Inc.5$206
Adamas Pharmaceuticals, Inc.10$183
Avanir Pharmaceuticals, Inc.12$180
Sanofi7$154
Grifols USA, LLC7$144
GE HealthCare5$141
Jazz Pharmaceuticals Inc.5$132
Vanda Pharmaceuticals Inc.5$129
Inspire Medical Systems, Inc.2$120
Amneal Pharmaceuticals LLC6$116
Sunovion Pharmaceuticals Inc.1$116
Supernus Pharmaceuticals, Inc.5$112
Insightec,inc1$110
Upsher-smith Laboratories LLC5$105
Kyowa Kirin, Inc.5$93
Livanova USA, Inc.5$92
Merz North America, Inc.2$86
Revance Therapeutics, Inc.2$78
Otsuka America Pharmaceutical, Inc.4$67
Sandoz2$53
Johnson & Johnson3$52
CSL Behring2$51
Takeda Pharmaceuticals U.S.A., Inc.2$50
Corium, LLC5$47
Tanabe Pharma America, Inc.2$41
Currax Pharmaceuticals LLC3$41
Catalyst Pharmaceuticals, Inc.2$36
Assertio Therapeutics, Inc.2$36
Vertical Pharmaceuticals, LLC2$36
Boston Scientific1$32
Mallinckrodt Enterprises LLC2$28
Zyla Life Sciences, Inc.2$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$206,568 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$917,370
Medicare patients
1,386
Services billed
43,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina25$32,694
Dalfampridine ErDalfampridine16$3,173
Baclofen33$1,382
Mirtazapine25$1,104
Carbidopa-LevodopaCarbidopa/Levodopa28$673
Gabapentin40$666
Duloxetine Hcl16$491
RivastigmineRivastigmine Tartrate11$446
Primidone18$432
Pramipexole DihydrochloridePramipexole Di-Hcl11$408
Donepezil Hcl14$405
Nortriptyline Hcl20$362
Sertraline Hcl11$145
Trazodone Hcl15$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$45,761$32,69425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.

Other neurology in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →